Justin Chakma - 02 Dec 2024 Form 4 Insider Report for ARS Pharmaceuticals, Inc. (SPRY)

Role
Chief Business Officer
Signature
/s/ Kathleen Scott, Attorney-in-Fact
Issuer symbol
SPRY
Transactions as of
02 Dec 2024
Net transactions value
-$1,133,019
Form type
4
Filing time
04 Dec 2024, 21:45:05 UTC
Previous filing
27 Nov 2024
Next filing
06 Dec 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SPRY Common Stock Options Exercise $37,800 +45,000 +33% $0.8400 181,380 02 Dec 2024 Direct
transaction SPRY Common Stock Sale $615,218 -45,000 -25% $13.67 136,380 02 Dec 2024 Direct F1
transaction SPRY Common Stock Options Exercise $2,738 +3,260 +2.4% $0.8400 139,640 03 Dec 2024 Direct
transaction SPRY Common Stock Options Exercise $35,062 +41,740 +30% $0.8400 181,380 03 Dec 2024 Direct
transaction SPRY Common Stock Sale $593,402 -45,000 -25% $13.19 136,380 03 Dec 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SPRY Stock Option (Right to Buy) Options Exercise $0 -45,000 -93% $0.000000 3,260 02 Dec 2024 Common Stock 45,000 $0.8400 Direct F3
transaction SPRY Stock Option (Right to Buy) Options Exercise $0 -3,260 -100% $0.000000 0 03 Dec 2024 Common Stock 3,260 $0.8400 Direct F3
transaction SPRY Stock Option (Right to Buy) Options Exercise $0 -41,740 -18% $0.000000 194,640 03 Dec 2024 Common Stock 41,740 $0.8400 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The weighted average sale price for the transaction reported was $13.6715, and the range of prices were between $13.324 and $14.035. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F2 The weighted average sale price for the transaction reported was $13.1867, and the range of prices were between $13.00 and $13.38. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F3 Immediately exercisable.